J Korean Surg Soc.
2000 May;58(5):607-613.
Induction Chemotherapy for Breast Cancer: A case control study
- Affiliations
-
- 1Department of Surgery, School of Medicine, Keimyung University.
Abstract
-
PURPOSE: Preoperative chemotherapy has been extensively used in inoperable or locally advanced breast
cancer to achieve tumor reduction and, thus, to facilitate extensive surgery. METHODS: A hospital-based
case-control study was carried out to identify the effect of induction chemotherapy on breast cancer.
49 patients with breast cancer were treated with initial chemotherapy between October 1986 and June
1998. 43 patients were treated with three courses of the CMF regimen (cyclophosphamide and metho
trexate and 5-fluorouracil), four patients with three courses of the FEC regimen (5-fluorouracil, epirubicine
and cyclophosphamide), two patients with three courses of the FAC regimen (5-fluorouracil, adriamycin
and cyclophosphamide). RESULTS: The response, rate to induction chemotherapy was 83.7% including 4%
complete response, and there were no significant differences in response rates according to the chemo
therapy regimen. At a mean follow-up of 51.9 months, recurrence and distant metastasis were observed
in 32.7% and 18.4% of the patients, respectively. The five-year disease- free survival rate of the patients
in the induction group was lower than that of the patients in the control group (35.5+/-8.7% versus 59.9+/-9.0%), but the five-year overall survival rate in the induction group was higher than control group (88.7
5.3% versus 76.9+/-6.6%). CONCLUSIONS: Preoperative induction chemotherapy is a useful treatment option
for patients with locally advanced breast cancer. Also, there is an improvement in the five-year overall
survival rate for patients in the induction chemotherapy group compared with that for patients in the
age- and stage-controlled postoperative adjuvant chemotherapy group.